Recent Company News

• 07:02 AM ET May 01, 2026
  

  Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling (CHF 3.21, 0.00)

• 04:54 AM ET Feb 26, 2026
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 04:48 PM ET Apr 19, 2026
  

  Molecular Partners presents three posters at AACR 2026, new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712 (CHF 3.27, 0.00)

• 02:35 PM ET Apr 17, 2026
  

  StreetAccount Summary: Notable Drug Events expected for the week of 19-Apr

• 02:16 PM ET Apr 10, 2026
  

  StreetAccount Summary: Notable Drug Events expected for the week of 12-Apr

• 02:06 AM ET Mar 19, 2026
  

  Molecular Partners to present new preclinical data on Radio-DARPins at the 3rd Global Radiopharmaceuticals Development Summit, taking place in Shanghai, China on 19-20 Mar (CHF 3.70, 0.00)

• 04:39 PM ET Mar 17, 2026
  

  Molecular Partners to present three posters at AACR 2026 Annual Meeting (CHF 3.15, 0.00)

• 04:22 PM ET Mar 12, 2026
  

  Molecular Partners reports financial results for FY25; provides pipeline update (CHF 3.77, 0.00)

• 03:19 PM ET Mar 02, 2026
  

  Transcript Intelligence: Molecular Partners at TD Cowen Health Care Conference